CYSTEAMINE VS. CYSTAMINE TREATMENT OF CORNEAL CRYSTAL ACCUMULATION

半胱胺对比

基本信息

  • 批准号:
    2574536
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

A successful, controlled clinical trial of cysteamine vs. placebo has proved the efficacy of cysteamine eyedrops in the treatment of removing crystals from patients with nephropathic cystinosis. Because cysteamine preparation is dispensed at room temperature and room temperature cysteamine oxidizes the disulfide cysteamine, it has been suggested that this more stable compound be studied for safety and efficacy. To date, there have been no studies on the clinical efficacy of the disulfide, although current speculation is that the compound will be pharmacologically active at similar concentrations. No animal model for cystinosis exists; clinical efficacy can be determined only through limited human clinical trials. Preceding this, however, experience with toxicity was necessary, and a study was performed in rabbits to determine the range of toxicity of the disulfide compound prior to its use in a clinical trial. Twenty-four rabbits were observed in a double-blind study for ocular toxicity testing of cysteamine disulfide, cystamine. Complete data are available, but in summary, the reaction to 0.5 percent and 1 percent was essentially no different from the placebo. Cysteamine 2 percent showed both clinical and histopathologic evidence of blepharitis and conjunctivitis. This study is to perform a randomized, controlled, double-masked clinical trial of cysteamine vs. cystamine for equivalency in removing crystals from the cornea and in maintaining a "crystal-free" or near crystal-free cornea.
一项成功的半胱胺与安慰剂对照临床试验

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

M KAISER-KUPFER其他文献

M KAISER-KUPFER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('M KAISER-KUPFER', 18)}}的其他基金

CYSTEAMINE VS. CYSTAMINE TREATMENT OF CORNEAL CRYSTAL ACCUMULATION
半胱胺对比
  • 批准号:
    5203267
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

New Aminothiol Prevention of X-Ray-Induced Mouse Mutagenesis and Tumorigenesis
新的氨基硫醇预防 X 射线诱导的小鼠突变和肿瘤发生
  • 批准号:
    8703290
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS
氨基硫醇治疗肾病性胱氨酸贮积症
  • 批准号:
    6297099
  • 财政年份:
    1998
  • 资助金额:
    --
  • 项目类别:
AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS
氨基硫醇治疗肾病性胱氨酸贮积症
  • 批准号:
    6113426
  • 财政年份:
    1998
  • 资助金额:
    --
  • 项目类别:
AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS
氨基硫醇治疗肾病性胱氨酸贮积症
  • 批准号:
    6274660
  • 财政年份:
    1997
  • 资助金额:
    --
  • 项目类别:
AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS
氨基硫醇治疗肾病性胱氨酸贮积症
  • 批准号:
    6244626
  • 财政年份:
    1997
  • 资助金额:
    --
  • 项目类别:
AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS
氨基硫醇治疗肾病性胱氨酸贮积症
  • 批准号:
    6303529
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS
氨基硫醇治疗肾病性胱氨酸贮积症
  • 批准号:
    5217669
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了